Arcus Biosciences Inc. (RCUS)

AI Score

Unlock

8.42

0.31 (3.82%)

At close: Apr 24, 2025, 3:59 PM

8.41

-0.11%

After-hours: Apr 24, 2025, 04:25 PM EDT

Dividends

No dividend history available for Arcus Biosciences Inc..

Pro Subscription

Upgrade now for unlimited access to all data and tools.

Dividend Definition

Dividends are payments made by a company to its shareholders, typically derived from its profits. They represent a portion of earnings distributed to investors as a reward for holding shares. Dividends do not account for retained earnings or reinvestments and are therefore different from a company's total profits.

Full Definition

Related Stocks

Company	Dividend Yield

Dividend Rankings

RCUS News

1 day ago · Arcus Biosciences Announces New Employment Inducement Grants - businesswire.com
3 days ago · Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update - businesswire.com
3 weeks ago · Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts - seekingalpha.com
1 month ago · Arcus Biosciences to Participate in Two Upcoming Investor Conferences - businesswire.com
1 month ago · Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates - zacks.com
2 months ago · Biotechs Highlight 6 Stocks Insiders Are Buying Now - 247wallst.com
2 months ago · Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering - businesswire.com
2 months ago · Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock - businesswire.com
2 months ago · New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer - businesswire.com
2 months ago · Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium - businesswire.com